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This dissertation is comprised of three manuscripts reporting on adults living with cystic 
fibrosis (CF), self-management behaviors and health outcomes. Chapter I explores what is 
known about adults living with CF and the factors impacting their self-management, including 
the complexities of a health maintenance regime required for survival while integrating and 
balancing the realities of adulthood. The review of literature provides direction for future 
research and implications for adult-focused CF studies. Chapter II is a manuscript describing the 
characteristics of prognostic survival models utilized in adult CF research and provides an 
overview of their development, validation, predictive values, and prognostic outcomes. Models 
were evaluated for applicability to research and clinical practice and it is suggested a reliable 
prognostic survival model which is easily adaptable to research and practice exists. This 
prognostic survival model is highlighted further as the health outcomes measure utilized in 
Chapter III. In this chapter, the findings of a longitudinal, descriptive repeated measures study 
exploring improved health outcomes among adults living with CF who reported adherent self-
management behaviors regarding their prescribed treatment plan are described. Health outcomes 
improved for those participants in our study who adhered to their disease modifying treatments, 
showing a statistically significant reduction in risk for transplant or death within the next four 
years. Additional inquiry into adherence levels and barriers to maintaining adherence among 
adults with CF is warranted. 
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CHAPTER I:  THE IMPACT OF LIVING WITH CYSTIC FIBROSIS FOR ADULTS 
Chapter I includes a review of adult cystic fibrosis literature which highlights the 
complexities of day to day self-management and elements influential for guiding needed 
research. The manuscript is planned for submission to Chronic Illness for publication.  
Abstract 
 Advances in modern medicine have led to progressive treatment options and an increase 
in longevity for adults living with cystic fibrosis (CF). The CF community today is comprised 
mostly of adults, yet adult research samples routinely incorporate child and adolescent subjects 
or account for the caregiver, parent, or support person when discussing home management of 
care. The reality of adulthood may include balancing responsibilities of home, work, school, and 
social life and may require complete independence without the benefit of the support network 
many experience during childhood. Daily self-management of a complex prescribed treatment 
plan is required if continued treatment success and positive health outcomes are to be achieved. 
However, minimal literature is available describing many important dimensions including: 
research focused exclusive to living as an adult with CF, the factors impacting self-management, 
and recommendations for future research. Here, we present what is known about adults living 
with CF and the factors that impact self-management. 
Introduction 
Until recently, a diagnosis of CF rarely included survival to adulthood (Simmonds, 
Cullinan, & Hodson, 2009). Today, more than 53% of the CF patient population are 18 years of 
age or older with survival possible into the early 40’s (Cystic Fibrosis Foundation, CFF, 2016a, 
2017). Current advancements in genetic research, improvement in treatment, pharmaceutical 
enhancements, and the establishment of specialized CF care centers have all contributed to the 
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improved survival rates among adults living with CF (Rubin et al., 2017; Sawicki, Sellers, & 
Robinson, 2009). However, the success of many of these advances rely primarily on the adult CF 
patients’ cooperation and feedback in the maintenance of a complex daily self-management 
regimen.  
Regardless of age or symptomology, CF patients are prescribed similar health 
maintenance routines despite difference in personal experiences, self-management behaviors and 
outcomes. A number of factors are influential on disease severity and health outcomes among 
adults living with CF, including the socioeconomic environment, cultural and community 
influences, resources that mitigate stress, prescribed treatment adherence, and self-management 
skill (Cohen-Cymberknoh, Shoseyov, & Kerem, 2011; Sawicki et al., 2013; Schechter, 2011). 
However, information exclusive to the adult CF population and self-management of their disease 
is lacking. If researchers and clinicians hope to influence the health and wellbeing of a 
population which comprises over half of all those living with CF today, more insight into their 
lives must be provided. The purpose of this paper is to present what is known about adults living 
with CF and the factors that impact self-management. 
Cystic Fibrosis  
Cystic Fibrosis is the most common inherited genetic disease of the lungs and digestive 
system affecting about 30,000 people in the United States and 70,000 people worldwide, with 
adults being more than half of those impacted today (CFF, 2016a; 2017). The etiology of CF 
includes mutations of a single gene, which encodes the CF trans-membrane conductance 
regulator or CFTR (Hopkins, 1996). This alteration of the CFTR causes irregular sweat glands 
and abnormally thickened secretions of the respiratory, gastrointestinal, and reproductive tracts, 
which characterize the clinical symptoms of the disease (Wilmott & Fiedler, 1994). The disease 
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manifests itself most seriously in the lungs and pancreas. Potential complications caused by 
CFTR dysfunction include increased inflammatory response, defects in bacterial phagocytosis, 
changes in antimicrobial properties of airway mucus, and susceptibility to opportunistic bacteria, 
all of which are associated with shortened survival (Terheggen-Lagro, Rijkers, & van der Ent, 
2005; Li et al., 2005). Those with CF may experience mild gastrointestinal (GI) or pulmonary 
problems, whereas others may experience severe malabsorption problems and fatal pulmonary 
complications (Carpenter & Narsavage, 2004). This incurable, progressive, multisystem disease 
harms numerous organs, complicates many of the body’s normal processes, and shortens life 
expectancy.  
Daily Management  
Living with CF requires daily management of the disease and symptom manifestations. 
Outcomes and disease progression vary among adults living with CF, which stresses the 
importance of understanding self-management of a chronic illness among populations who 
essentially ‘grew up’ with a chronic illness. Many adults living with CF today are college 
graduates, working, establishing relationships, becoming parents, and leading independent lives 
(Al-Yateem, 2012; CFF, 2016a).  
Transition is a unique process experienced only by those populations afflicted with a 
chronic illness throughout multiple developmental stages of life. It is a vital component to the 
progression and development of self-management behaviors and skills, which makes it key to the 
phenomenon of adherence among adults with CF. Transition has been identified as a significant 
period in the life of young adults with CF, as well as other chronic illness sufferers (Al-Yateem, 
2012; Lotstein, 2009; Towns & Bell, 2011). Those with chronic illness who are reaching 
adulthood require age-appropriate care and counseling regarding adult-focused concerns, such as 
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self-management, employment, and reproduction (Duguépéroux et al., 2008). Support is vital 
during this stressful time and is associated with better post-transition outcomes. Better self-
management behavior has been found among those who attend chronic disease support groups 
(Chiou, 2014). However, within the CF community, opportunities for personal interaction 
between patients for education or mutual support are not generally feasible due to possibility of 
cross-contamination with resistant pulmonary bacteria (Tuchman, Schwartz, Sawicki, & Britto, 
2010).  
People with chronic illness differ in their readiness and abilities to spend time, energy, 
and focus on their illness at varying points in their lives (Clark & Gong, 2000; Hwu & Chin-
Ching, 2006). Adults living with CF are dependent on daily self-management for continued 
quality and quantity of life, however, it is commonplace to identify variability in self-
management behavior, such as, adherence to all prescribed treatment plan recommendations 
(Abbot, Dodd, Bilton, & Webb (1994); Conway, Pond, Hamnett, & Watson (1996); O’Sullivan, 
Sullivan, Higuchi, & Montgomery (2011).  
 The usual recommended treatment includes multiple inhaled therapies, airway clearance 
two times per day, oral medications, and boosting calories to 110% to 220% of the recommended 
daily allowance (Quittner et al., 2012). The time-consuming daily regimen involves completing 
several health maintenance treatments (Figure 1), maintaining weight, and engaging in aerobic 
activities. For adults living with CF, self-care behaviors may include performing chest 
physiotherapy, use of airway clearance devices, taking prescribed medications, and monitoring 
respiratory and nutritional status (Baker & Denyes, 2008; Hockenberry & Wilson, 2013).  
Diagnosis of CF generally occurs early, usually within the first years of life, so health 
management must begin during infancy. Ideally, as one grows up with CF, responsibility for 
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maintaining the health and treatment regimen gradually transitions from the family members to 
the child. Children with CF must learn to recognize and treat symptoms as well as signs of 
serious pulmonary exacerbations (Quittner, Espelage, Levers-Landis, & Drotar, 2000b).  
Aggressive and arduous CF treatment regimens are required on a daily basis, as the child 
with CF becomes aware that failure to manage the prescribed treatments and medications 
adequately can quickly lead to serious decline (Li et al., 2005). Research participants have 
expressed difficulty in physically integrating the practicalities involved in managing a 
recommended healthcare regimen into a busy lifestyle (Badlan, 2007).  
Adherence to prescribed treatments among those with chronic illness is a global issue and 
not just a need to label patients as compliant or noncompliant. It is a problem of humans in 
general. Adherence itself needs reframed and rethought to be one of the most challenging areas 
of chronic disease management (Wildman & Hoo, 2014). Overall, it is estimated that adherence 
rates are 30-50% among the general population (Wildman & Hoo, 2014) and 35-75% among 
users of chronic pulmonary medication, depending on drug and age (Eakin et al., 2011; Daniels 
et al., 2011). Within primary care, at least $300 million worth of medicines are wasted due to 
poor adherence for self-care management by those with chronic conditions, such as asthma 
(Horne & Weinmann, 2002).  
Recently, researchers undertook the task of standardizing methods for reporting 
adherence to inhaled therapies among adults with CF (Hoo et al, 2016). The lack of evidence 
affirming how much adherence is enough among adults with CF makes determination of this 
standard an ongoing process (Kettler, Sawyer, Winefield, & Greville, 2002). The recent work 
being done to accurately calculate adherence is needed even beyond inhaled therapy and should 
be expanded into determining minimum necessary adherence for each portion of prescribed 
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treatments and medications. Researchers must ask themselves, for each portion of a prescribed 
treatment plan, what is the appropriate ‘dose’ to be adherent.     
Impact of Adherence  
Researchers and clinicians believe the impact of self-management skills, including 
adherence to prescribed treatment plans among adults living with CF, explains the significant 
variation in patient outcomes (Schechter, 2011; Schechter & Gutierrez, 2010; Zemanick et al., 
2010). Severity of lung disease is the key to length and quality of life among patients with CF 
(van Gool et al., 2013). Researchers suggest poor self-management skill is associated with 
exacerbation of pulmonary dysfunction and lower baseline lung function (Eakin & Reikert, 
2013; Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011). Adherence rates among adults 
with CF are similar to those living with other chronic illnesses (Kettler et al., 2002; Sawicki et 
al., 2009). However, adults living with CF require adherence to a variable and involved daily 
regimen, frequent follow up visits with multiple health specialists, and constant self-monitoring, 
entailing necessity of multiple adherent behaviors in addition to navigating the common daily 
stressors of adulthood. Limited empirical evidence regarding adherence as it relates to health 
outcomes among adults living with CF constrains the ability of health professionals to make the 
needed population sensitive recommendations or offer interventions which lessen patient burden 
related to self-management behavior. 
At times, patients with a chronic and/or terminal illness may consider self-management 
futile. Cystic fibrosis is a progressive illness, but in a study on CF treatment, where the 
researchers assumed patients did not improve their health state, 83 of their 2255 (0.03%) enrolled 
subjects did improve lung function over a three-year time frame (van Gool et al., 2013). Self-
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management behaviors may influence the variability in disease progression and health outcomes 
among those living with CF. 
There is a gap between current treatment success rates and those believed to be 
achievable among chronic disease sufferers in the United States; this gap has been attributed in 
part to issues with self-management and lack of patients’ ability to adhere to recommendations 
(Institute of Medicine [IOM], 2003; Viswanathan et al., 2012). One reason thought to contribute 
to problems with self-management of chronic disease was treatment costs. The average annual 
cost for individual CF treatment is more than $40,000 accumulating to approximately $306, 332 
over a lifetime, with the majority of costs consisting of hospital admissions (58%), followed by 
pharmaceuticals (29%), medical services (10%), complications (2%), and diagnostic testing (1%) 
(CFF, 2012; Lieu et al., 1999; van Gool et al., 2013, Rubin et al, 2017). The CFF (2012) stated 
that one in four CF patients skipped doses of their medicine or purposefully took smaller doses 
because of cost, and nearly one in five delay seeking care for the same reason. 
Although it is established that adherence influences outcomes, evidence is limited on 
whether approaches to improve adherence are broadly applicable or affect long-term adherence 
and health outcomes (Viswanathan et al., 2012). Among CF patients six years of age and older, 
researchers found poor adherence to nebulized medication as a significant predictor of having a 
pulmonary exacerbation requiring intravenous (IV) antibiotic therapy (Eakin et al., 2011). 
Researchers report lower baseline lung function (Eakin et al., 2011), higher costs (Nasr, Chous, 
Villa, Chang, & Broder, 2013), and increased hospitalizations (Briesacher et al., 2011) are 
associated with poor adherence to CF medication therapy. CF researchers have limited studies to 
one medication or therapy and included children and adolescents, as well as adults. This 
highlights the need for continued inquiry specifically targeting the adult CF population and 
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integrating the variable adult CF treatment regimen into data collections and analysis to add to a 
lacking body of knowledge regarding adherence and health outcomes.  
Financial Impact 
Funding and affordability of treatment programs designed for adults living with CF 
remains a challenge. Insurance coverage plays a significant role in the health and wellbeing of 
people living with chronic illness in the United States. In 2010, the Patient Protection and 
Affordable Care Act (ACA) was signed into law in the United States (Lyon, Douglas, & Cooke, 
2014). Due to the ACA prohibiting pre-existing condition penalties or benefit ceilings, and its 
push for expansion in state Medicaid coverage, it seemed as though the ACA was going to be of 
significant benefit to those living with CF. However, the CF population and their healthcare 
providers are experiencing continued difficulty with the U.S. healthcare system (Nathanson, 
Ramírez-Garnica, & Wiltrout, 2005; O’Sullivan et al., 2011).  While the Medicaid expansion is 
an important step toward limiting insurance-related disparities, studies have shown poorer 
outcomes among patients with lung disease who utilize Medicaid compared with those enrolled 
in private insurance. (Slatore, 2010; Lyon et al., 2014). Advocacy for improvement in policies 
and support for inclusive health insurance expansions within the research arena may have the 
potential to facilitate advancement in health outcomes and reduce barriers for patients and 
practitioners within the CF community. 
Chronic illness often interferes with maintaining continuous full-time employment, thus 
limiting access to private health insurance. In addition, complex medical treatment results in 
reaching maximum lifetime insurance benefits. The CFF found among those living with CF, half 
are spending at least $300 on insurance premiums and at least $200 on out-of-pocket costs for 
CF-related medication, 14% had reached their annual limit on insurance coverage, and 3% had 
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reached their lifetime limit (CFF, 2012; CFF, n.d.). According to researchers who reported the 
yearly expense for all medical necessities, the average annual cost of survival for a person living 
with CF is $46,000 (Ouyang, Grosse, Amendah, & Schechter, 2009).  However, a CF patient has 
the potential for unpredictable exacerbation requiring increased medication usage and 
hospitalizations. In a recent study, annual costs associated only with worsening lung symptoms 
among patients ranged from $30,066 to $119,862 (Rubin et al, 2017).   
National guidelines recommend CF patients attend outpatient appointments at least once 
every four months (CFF, 2016a). Nathanson and colleagues (2005) suggested those with 
managed care, or requiring a referral prior to seeing a specialist, may not have equal access to 
experts in CF, as managed care patients attended appointments significantly less frequently than 
those in non-managed care, thus were not seeing their CF specialized healthcare provider as 
often as recommended, or not at all. The ACA allows for variability in what is termed, ‘essential 
health benefits’ when expanding state Medicaid coverage. This may interrupt care services and 
treatment for patients with pulmonary diseases, including CF, who utilize Medicaid.  
The new essential health benefits may limit who is deemed an essential provider, limiting 
access to CF specialists, and it does not guarantee access to all of the medication determined to 
be necessary in individual cases. Instead, it allows allocation of a specific number of medications 
in each drug class, limiting a provider’s choice in treatment or a patient’s ability to afford needed 
prescriptions (Cheng, Wise, & Halfon, 2014; Kraft, 2012; Lyon et al., 2014). This can be 
devastating for CF patients’ prognosis as many of their critical medications lack a cheaper, 
generic alternative. Combination medications, such as those prescribed for inhalers and 
nebulizers, are also not provided for in the current ACA law, which may threaten the health of 
adults living with CF, as these therapies are required several times daily to limit deadly lung 
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exacerbation (Billings, 2013; Kraft, 2012; Lyon et al., 2011). Additionally, necessary durable 
medical equipment, such as nebulizers, interpretation of pulmonary function tests, counseling for 
end-of-life, and palliative care are not included in the minimum benefit standards for Medicaid 
or Medicare recipients (Bisgaier & Rhodes, 2011; Kraft, 2012).  
Biological and Psychological Impact    
CF contributes to impaired physical functioning, loss of independence, emotional 
distress, and changes in self-identity (Badlan, 2007; CFF, 2016a; Simmonds et al., 2009). In 
addition to frequent illness, persons with CF face many serious problems in daily living, in some 
instances due to physical limitations caused by pain. Hubbard, Broome, & Antia, 2005). In one 
study, 55.6% of participants with CF reported pain on a daily basis (Hubbard, Broome & Antia, 
2005; Sawicki et al., 2009; Simmonds et al., 2009). Adults with CF live with the reality that their 
diagnosis is progressive and fatal. As life expectancy is well documented, adults living with CF 
must face their mortality early and may either learn to appreciate life more and participate in 
their healthcare, (Peterson, 2006), or it may cause the person to feel powerless and lack 
motivation to contribute to their own wellbeing (Carpenter & Narsavage, 2004). Researchers 
studying hopes and fears among adults living with CF discovered, in addition to worry 
surrounding premature death and potential suffering, participants had hopes of experiencing 
normal relationships, child rearing, and employment (Higham, Ahmed, & Ahmed, 2013).  CF, as 
a chronic illness with no current available cure, imposes a tremendous burden on the individual’s 
physical and mental wellbeing.  Researchers need to remain mindful of these facts when 





Social and Cultural Impact  
Adults living with CF may choose to attend college, become employed, marry or have 
families. They do so despite the challenges created by their illness. Genetic conditions like CF 
may be stigmatizing or involve feelings of shame and embarrassment within the family structure 
(Simmonds et al., 2009). The experience of social exclusion is reported frequently (Peterson, 
2006). The weight CF has on influencing patients’ decisions to engage in social activities, like 
travel, play with one’s own children, or sports is significant (Simmonds et al., 2009). Many 
believe these activities could pose a threat to their fragile state of health. Adults with CF describe 
the unpredictability of symptoms and treatment regimens and the impact on life plans 
(Simmonds et al., 2009). People are often forced to reassess their priorities in life, and in some 
cases, ‘plan for the worst’ (Peterson, 2006).  
 Numerous factors burden adults living with CF and influence their physical, 
psychological, social, and vocational wellbeing. Researchers among this population must 
consider these influencing factors when making decisions regarding needed studies, determining 
research burden for participants, and controlling for variable in outcomes research. 
Needed Research 
 The chronic nature of CF may influence the quality and quantity of life among adults 
living with CF and limited research regarding this phenomenon prompts a pressing need to 
increase adult CF nursing research. Specifically, adherence research about patients who self-
manage may provide needed insight into the nature of health challenges for patients with CF, 
perhaps facilitating the provider’s ability to give the best care (Riegel, Jaarsma, & Stromberg, 
2012). Although research among adults with CF is emerging, much of the self-management 
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research is lacking an association to health outcomes and those that do, are either not exclusive 
to adults with CF, or are limited to adherence of one aspect of the prescribed treatment plan.   
 Measurement of adherence is a vital component to self-management research, however 
many researchers are reporting difficulty (Eakin et al., 2011; Faulkner, Taper, & Scott, 2012; 
Kettler et al., 2002; Viswanathan et al., 2012). Many measurement tools developed for CF 
research must be modified for use among the adult population or simply do not exist. Objective 
measures for adherence are preferred but feasibility is questionable as Medication Event 
Monitoring Systems (MEMS) are costly. Safe guards are non-existent to ensure patients are 
adherent to the prescribed regimen and not just accessing medication vials, nebulizers, and vest 
machines, but whether they are actually utilizing them. Self-report discrepancies can often be 
interpreted as patients attempting to deceive, but can reflect simple difficulties in recollection 
(Wildman & Hoo, 2014). A careful review of literature warrants a need for development of a 
reliable and valid, yet publicly available, tool that is able to distinguish the level of adherence. 
Pharmaceutical refill counts are a promising objective measure, but again, there lacks certainty 
the medication is utilized after it is filled and the patients’ pharmacy is involved with only 
portions of the recommended treatment regimen for adult CF patients (Wildman & Hoo, 2014). 
Feasibility and intervention studies utilizing adherence and self-management technology among 
adult CF patients may be vital to improving data collection.  
 Improved understanding of the theoretical knowledge that underpins the complexities of 
adherence among the aging population may benefit the CF community (Banning, 2009). An 
important next step is to examine the relationship between adherence trajectories and health 
outcomes, including pulmonary functioning, nutritional status, and health-related quality of life. 
Researchers must identify optimal levels of adherence, which may promote the best health 
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outcomes (Modi et al., 2010). There is little known research about the relationship between level 
of adherence to a prescribed regimen and health outcomes among adults living with CF. This is 
of significant concern as researchers find adherence to medications is poor among people with 
CF (Eakin et al., 2011; Cohen-Cymberknoh et al., 2011). Poor adherence may be associated with 
accelerated decline in lung function and the need for increased interventions (Eakin & Reikert, 
2013).  
 Treatment complexity coupled with barriers to self-management of chronic illness 
experienced by adults with CF result in varying levels of adherence. The treatment demands 
placed upon adults with CF are extraordinary when compared with most other chronic illnesses 
(Kettler et al., 2002). Research into dynamics of treatment burden and perceived burden overtime 
and the effect on self-management in adults with and without changes in treatment complexity 
would be of considerable research interest to the CF community (Sawicki et al., 2013). In 
addition, given the lack of agreement among CF specialists and healthcare teams regarding 
which treatments are most important, further research interpreting and determining the priority of 
adherence to each treatment within the health maintenance regimen would be of significant 
importance (Quittner et al., 2000a; Kettler et al., 2002). Efforts to quantify necessary adherence 
may facilitate development of more manageable prescribed treatment plans and limit patient 
perceived burden. 
 As adults living with CF face new challenges, additional research is needed to examine 
how patients participate in management of their CF over the long term (Carpenter & Narsavage, 
2004). New policies for training skills in self-management and health literacy using collaborative 
models are needed, especially as adult CF patients attempt to maneuver independently within a 
complicated healthcare system (James, Boyle, Bennett, & Bennett, 2012; Lloyd, Ammary, 
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Epstein, Johnson, & Rhee, 2006). More research is needed to support the policy change needed 
to impact and introduce adult focused initiatives for CF. 
 Future researchers may provide needed information to health care professionals in order 
to promote and facilitate self-management among the adult CF population. Examining the 
motivational attributes present in the self-managing adult with chronic illness experiencing 
desired outcomes would be beneficial for guiding person-centered interventions. Costs and 
benefits of technology for self-management of chronic illness are necessary for future research 
(Stellefson et al., 2013). Utilization of technology for personal health databases in self-
management of CF could be an important contribution. Research focusing on the specific nature 
and meaning of the experiences among adults living with CF is necessary. The potential exists to 
improve the quality and quantity of life among this vulnerable population by exploring research 
questions pertinent to their needs.  
Conclusion 
Advances in health care have extended the lives of those living with CF into adulthood 
resulting in transition from dependence upon caregivers and pediatric care settings to self-
management of symptoms and participation in treatment planning. The chronic nature of CF 
requires self-management, which may influence the quality of life and health outcomes among 
adults living with CF. Limited research regarding the adult living with CF prompts a pressing 
need for researchers to explore phenomena utilizing exclusively adult samples. As adults living 
with CF face new challenges, such as, issues surrounding healthcare access, disclosure of their 
disease, education, employment, marriage, childbirth, and end-of-life decisions, understanding 
the experiences of adults living with CF is necessary. An aging CF population requires 
continuous self-management and adherence to multiple daily treatments and medications, 
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therefore, evidence-based recommendations addressing the adult CF population may impact 
societal and economic burdens, preventable hospital admissions, morbidity, and mortality. 
Researchers who focus on adults living with CF, may provide needed insight into the nature of 













Abbott, J., Dodd, M., Bilton, D., & Webb, A. K. (1994). Treatment compliance in adults with 
cystic fibrosis. Thorax, 59, 115-120.  
Al-Yateem, N. (2012). Child to adult: Transitional care for young adults with cystic fibrosis. 
British Journal of Nursing, 21(14), 850-854.  
Badlan, K. (2007). Young people living with cystic fibrosis: An insight into their subjective 
experience. Health & Social Care in the Community, 14(3), 264-270.  
Baker, L. K., & Denyes, M. J. (2008). Predictors of self-care in adolescents with cystic fibrosis: 
A test of Orem’s theories of self-care and self-care deficit. Journal of Pediatric Nursing, 
23(1), 37-48.  
Banning, M. (2009). A review of interventions used to improve adherence to medication in older 
people. International Journal of Nursing Studies, 46(11), 1505-1515.  
Billings, P. G. (February 21, 2013). [a letter from Paul G. Billings, Senior Vice President of the 
American Lung Association to Kathleen Sebelius, Secretary of the Department of Health 
and Human Services]. Retrieved from: http://www.lung.org/get-
involved/advocate/advocacy-documents/medicaid-ehb-cost-sharing-comments-2-21-
13.pdf  
Bisgaier, J. & Rhodes, K. V. (2011). Auditing access to specialty care for children with public 
insurance. New England Journal of Medicine, 364, 2324-2333. 
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011). 
Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary 
Medicine, 11(1), 5-5. doi: 10.1186/1471-2466-11-5  
 
17 
Carpenter, D. R. & Narsavage, G. L. (2004). One breath at a time: Living with cystic fibrosis. 
Journal of Pediatric Nursing, 19(1), 25-32.  
Cheng, T. L., Wise, P. H., & Halfon, N. (2014). Promise and perils of the affordable care act for 
children. JAMA: Journal of the American Medical Association, 311(17), 1733-1734. 
doi:10.1001/jama.2014.930  
Chiou, C. J. (2014). Diabetes self-care behaviors and disease control in support group attenders 
and nonattenders. Journal of Nursing Research, 22(4), 231-241. doi: 
10.1097/jnr.0000000000000053. 
Clark, N. & Gong, M. (2000). Management of chronic disease by practitioners and patients: are 
we teaching the wrong things? BMJ: British Medical Journal (International Edition), 
320(7234), 572-575. 
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011). Managing cystic fibrosis: 
Strategies that increase life expectancy and improve quality of life. American Journal of 
Respiratory & Critical Care Medicine, 183(11), 1463-1471. doi:10.1164/rccm.201009-
1478CI  
Conway, S., Pond, M. N., Hamnett, T., & Watson A. (1996). Compliance with treatment in adult 
patients with cystic fibrosis. Thorax, 51, 29-33.  
Cystic Fibrosis Foundation, CFF (2017). 2016 Cystic Fibrosis Foundation Patient Registry 
Highlights. Bethesda, Maryland. Retrieved from 
https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Cystic-
Fibrosis-Foundation-Patient-Registry-Highlights.pdf 




Cystic Fibrosis Foundation, CFF (2016b). Cystic Fibrosis Foundation Patient Registry 2015 
Annual Data Report. Bethesda, Maryland. Retrieved from https://www.cff.org/Our-
Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report.pdf  
Cystic Fibrosis Foundation, CFF (2012). Cystic Fibrosis Patient Assistance Foundation (CFPAF) 




Cystic Fibrosis Foundation, CFF (n. d.). Priorities for the CF community in health care reform. 
Retrieved from https://www.cff.org/Get-Involved/Advocate/Health-Care-
Reform/Priorities-for-the-CF-Community-in-Health-Care-Reform/  
Daniels, T., Goodacre, L., Sutton, C., Pollard, K., Conway, S., & Peckham, D. (2011). Accurate 
assessment of adherence: Self-report and clinician report vs electronic monitoring of 
nebulizers. Chest, 140(2), 425-432. doi:10.1378/chest.09-3074 
Duguépéroux, I., Tamalet, A., Sermet-Gaudelus, I., Le Bourgeois, M., Gérardin, M., Desmazes-
Dufeu, N., & Hubert, D. (2008). Clinical changes of patients with cystic fibrosis during 
transition from pediatric to adult care. Journal of Adolescent Health, 43(5), 459-465.  
Eakin, M. N., Bilderback, A., Boyle, M. P., Mogayzel, P. J., & Riekert, K. A. (2011). 
Longitudinal association between medication adherence and lung health in people with 




Eakin, M. J. & Riekert, K. A. (2013). The impact of medication adherence on lung health 
outcomes in cystic fibrosis. Current Opinion in Pulmonary Medicine, 19(6), 687-691. 
doi:10.1097/MCP.0b013e3283659f45  
Faulkner, C., Taper, L., J., & Scott, M. (2012). Adherence to pancreatic enzyme supplementation 
in adolescents with cystic fibrosis. Canadian Journal of Dietetic Practice & Research, 
73(4), 196-199.  
Higham, L., Ahmed, S. & Ahmed, M. J. (2013). Hoping to live a “normal” life whilst living with 
unpredictable health and fear of death: Impact of cystic fibrosis on young adults Journal 
of Genetic Counseling 22(3) 374 - 383. https://doi.org/10.1007/s10897-012-9555-1  
Hockenberry, M. J. & Wilson, D. (2013). Wong’s Essentials of Pediatric Nursing, 9th ed. St. 
Louis, MO: Elsevier Mosby 
Hopkins, S. (1996). Advances in the treatment of cystic fibrosis. Nursing Times, 91, 40-41. 
Hoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016). 
Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: 
Methods to calculate “normative adherence”. Patient Preference and Adherence, 10. 887-
900. 
Horne, R. & Weinman, J. (2002). Self-regulation and self-management in asthma: Exploring the 
role of illness perceptions and treatment beliefs in explaining non-adherence to 
preventative medication. Psychology & Health, 17(1), 17-32.  
Hubbard, P. A., Broome, M. E., & Antia, L. A. (2005). Pain, coping, and disability in 
adolescents and young adults with cystic fibrosis: A web-based study. Pediatric Nursing, 
31(2), 82.  
 
20 
Hwu, Y. & Chin-Ching, Y. (2006). Exploring health behavior determinants for people with 
chronic illness using the constructs of planned behavior theory. Journal of Nursing 
Research (Taiwan Nurses Association), 14(4), 261-269. 
Institute of Medicine. 2003. Health Professions Education: A Bridge to Quality. Washington, 
DC: The National Academies Press. https://doi.org/10.17226/10681 . 
James, B. D., Boyle, P. A., Bennett, J. S., & Bennett, D. A. (2012). The impact of health and 
financial literacy on decision making in community-based older adults. Gerontology, 58, 
531-539. 
Kettler, L. J., Sawyer, S. M., Winefield, H. R., & Greville, H. W. (2002). Determinants of 
adherence in adults with cystic fibrosis. Thorax, 57(5), 459-464.   
Kraft, M. (2012). In Kathleen Sevelius, Department of Health and Human Services. American 
Thoracic Society Comments on the Department of health and Human Service’s essential 
health benefits for health insurance exchanges. Available from: 
http://thoracic.org/advocacy/comments-testimony/index.php.  
Li, Z., Kosorok, M. R., Farrell, P. M., Laxova, A., West, S., Green, C. G., . . . Splaingard, M. L. 
(2005). Longitudinal development of mucoid pseudomonas aeruginosa infection and lung 
disease progression in children with cystic fibrosis. JAMA: Journal of the American 
Medical Association, 293(5), 581-588.  
Lieu, T. A., Ray, G. T., Farmer, G., & Shay, G. F. (1999). The cost of medical care for patients 




Lloyd, L. L. J., Ammary, N. J., Epstein, L. G., Johnson, R., & Rhee, K. (2006). A 
transdisciplinary approach to improve health literacy and reduce disparities. Health 
Promotion Practice, 7(3), 331-335. 
Lotstein, D., Ghandour, R., Cash, A., McGuire, E., Strickland, B., & Newacheck, P. (2009). 
Planning for health care transitions: results from the 2005-2006 National Survey of 
Children with Special Health Care Needs. Pediatrics, 123(1), e145-52. 
doi:10.1542/peds.2008-1298 
Lyon, S. M., Benson, N. M., Cooke, C.R., Iwashyna, T. J., Ratcliffe, S. J., & Kahn, J. M. (2011). 
The effect of insurance status on mortality and procedural use in critically ill patients. 
American Journal of Respiratory Critical Care Medicine, 184, 809-815. 
Lyon, S. M., Douglas, I. S., & Cooke, C. R. (2014). Medicaid expansion under Affordable Care 
Act. Implications for insurance-related disparities in pulmonary, critical care, and sleep. 
Annals of the American Thoracic Society, 11(4), 661-667. doi: 
10.1513/AnnalsATS.201402-072PS 
Modi, A. C., Cassedy, A. E., Quittner, A. L., Accurso, F., Sontag, M., Koenig, J. M., & 
Ittenbach, R. F. (2010). Trajectories of adherence to airway clearance therapy for patients 
with cystic fibrosis. Journal of Pediatric Psychology, 35(9), 1028-1037. 
doi:10.1093/jpepsy/jsq015  
Nasr, S. Z., Chou, W., Villa, K. F., Chang, E., & Broder, M. S. (2013). Adherence to dornase 
alfa treatment among commercially insured patients with cystic fibrosis. Journal of 
Medical Economics, 16(6), 801-808. doi:10.3111/13696998.2013.787427  
 
22 
Nathanson, I., Ramírez-Garnica, G., & Wiltrout, S. A. (2005). Decreased attendance at cystic 
fibrosis centers by children covered by managed care insurance. American Journal of 
Public Health, 95(11), 1958-1963. doi:10.2105/AJPH.2004.059089  
O’Sullivan, A.K., Sullivan, J., Higuchi, K., & Montgomery, A.B. (2011). Health care utilization 
& costs for cystic fibrosis patients with pulmonary infections. Managed Care, 20, 37-44.  
Ouyang, L., Grosse, S. D., Amendah, D. D., & Schechter, M. S. (2009) Healthcare expenditures 
for privately insured people with cystic fibrosis. Pediatric Pulmonology, 44, 989-996.  
Petersen, A. 2006). The best experts: The narratives of those who have a genetic condition. 
Social Science & Medicine, 63(1), 32-42.  
Quittner, A. L., Drotar, D., Iveres-Landis, C., Slocum, N., Seidner, D., & Jacobsen, J. (2000a). 
Adherence to medical treatments in adolescents with cystic fibrosis: The development 
and evaluation of family-based intervention. In D. Drotar (Ed.), (pp. 383-407). Mahwah, 
NJ, US: Lawrence Erlbaum Associates Publishers.  
Quittner, A. L., Espelage, D. L., Ievers-Landis, C., & Drotar, D. (2000b). Measuring adherence 
to medical treatment in childhood chronic illness: Considering multiple methods and 
sources of information. Journal of Clinical Psychology in Medical Settings, 7(1), 41-54.  
Quittner, A. L., Sawicki, G. S., McMullen, A., Rasouiliyan, L., Pasta, D. J., Yegin, A., & 
Konston, M. (2012). Erratum to: Psychometric evaluation of the Cystic Fibrosis 
Questionnaire‐Revised in a national, US sample. Quality of Life Research, 21(7), 1279‐
1290. 
Riegel, B., Jaarsma, T., Stromberg, A. (2012). A middle-range theory of self-care of chronic 
illness. Advances in Nursing Science, 35(3), 194-204. 
 
23 
Rubin, J. L., Thayer, S., Watkins, A., Wagener, J. S., Hodgkins, P. S., & Schechter, M. S. 
(2017). Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis 
in the United States. Current Medical Research and Opinion, 33(4), 667-674.  
Sawicki, G. S., Ren, C. L., Konstan, M. W., Millar, S. J., Pasta, D. J., & Quittner, A. L. (2013). 
Treatment complexity in cystic fibrosis: Trends over time and associations with site-
specific outcomes. Journal of Cystic Fibrosis, 12(5), 461-467. 
doi:10.1016/j.jcf.2012.12.009  
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009). High treatment burden in adults with 
cystic fibrosis: Challenges to disease self-management. Journal of Cystic Fibrosis, 8(2), 
91-96. doi:10.1016/j.jcf.2008.09.007  
Schechter, M. S. (2011). Nongenetic influences on cystic fibrosis outcomes. Current Opinion in 
Pulmonary Medicine, 17, 448-454.  
Schechter, M. & Gutierrez, H. (2010). Improving the quality of care for patients with cystic 
fibrosis. Current Opinion in Pediatrics, 22(3), 296-301. 
doi:10.1097/MOP.0b013e328339550e 
Simmonds, N. J., Cullinan, P., & Hodson, M. E. (2009). Growing old with cystic fibrosis – The 
characteristics of long-term survivors of cystic fibrosis. Respiratory Medicine, 103, 629-
635. 
Slatore, C. G., Au, D. H., & Gould, M. K. (2010). American Thoracic Society disparities in 
healthcare group. An official American Thoracic Society systematic review: Insurance 
status and disparities in lung cancer practices and outcomes. American Journal of 
Respiratory Critical Care Medicine, 182, 1195-1205. 
 
24 
Stellefson, M., Chaney, B., Barry, A., Chavarria, E., Tennant, B., Walsh-Childers, K., . . . 
Zagora, J. (2013). Web 2.0 chronic disease self-management for older adults: a 
systematic review. Journal of Medical Internet Research, 15(2), e35. 
Terheggen-Lagro, S., Rijkers, G. T., & van der Ent, C. K. (2005). The role of airway epithelium 
and blood neutrophils in the inflammatory response in cystic fibrosis 
doi:10.1016/j.jcf.2005.05.007  
Towns, S. J. & Bell, S. C. (2011). Transition of adolescents with cystic fibrosis from pediatric to 
adult care. Clinical Respiratory Journal, 5(2), 64-75.  
Tuchman, L., Schwartz, L., Sawicki, G., & Britto, M. (2010). Cystic fibrosis and transition to 
adult medical care. Pediatrics, 125(3), 566-573. doi:10.1542/peds.2009-2791 
van Gool, Kees, Norman, R., Delatycki, M., B., Hall, J., & Massie, J. (2013). Understanding the 
costs of care for cystic fibrosis: An analysis by age and health state. Value in Health 
(Wiley-Blackwell), 16(2), 345-355. doi:10.1016/j.jval.2012.12.003  
Viswanathan, M., Golin, C. E., Jones, C. D., Ashok, M., Blalock, S. J., Wines, R. C., . . . Lohr, 
K. N. (2012). Interventions to improve adherence to self-administered medications for 
chronic diseases in the United States: A systematic review. Annals of Internal Medicine, 
157(11), 785-795.  
Wildman, M. & Hoo, Z. (2014). Moving cystic fibrosis care from rescue to prevention by 
embedding adherence measurement in routine care. Pediatric Respiratory Reviews, 1516-
18. doi:10.1016/j.prrv.2014.04.007 
Wilmott, R. W. & Fiedler, M.A. (1994). Recent advances in the treatment of cystic fibrosis. 
Pediatric Clinics of North America, 41, 431-451. 
 
25 
Zemanick, E. T., Harris, J. K., Conway, S., Konstan, M. W., Marshall, B., Quittner, A. L., . . . 
Accurso, F. J. (2010). Measuring and improving respiratory outcomes in cystic fibrosis 
lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis, 9(1), 1-






Figure 1. Typical daily adult CF health maintenance requirements and frequency. 
Prescribed Treatment Plan, by Quittner, A. L., 2000, Retrieved from 
http://www.psy.miami.edu/ksa_measures/pub.phtml. Copyright [2011] University of Miami. 




CHAPTER II:  EVALUATION OF PROGNOSTIC SURVIVAL MODELS FOR ADULTS 
WITH CYSTIC FIBROSIS 
Chapter II is systematic review of prognostic survival models utilized in CF research. 
Advances in genetics as well as other breakthroughs in clinical research warrants the 
determination of reliable, functional, and adult-focused measurement tools. The manuscript will 
be submitted for publication to Journal of Cystic Fibrosis, or Respiratory Care; or Chronic 
Illness  
     Abstract 
Indicators of mortality combined for the construction of prognostic models can assist 
clinicians with individualized treatment, validation of current therapy, self-management, 
optimization of transplant timing, and determination for end of life discussions and planning, 
however a widely-accepted model for adults with cystic fibrosis (CF) does not exist. A 
systematic review was conducted to evaluate prognostic survival models for use among adults 
with CF. We conducted a literature search for studies published between 1990 – 2017 in the 
PubMed, CINAHL, OVID, ProQuest and Google Scholar databases that described development 
of prognostic models of survival for CF patients utilizing more than one clinical indicator. 127 
articles were identified and after applying our inclusion and exclusion criteria, six articles 
remained for further evaluation. Most researchers utilized CF patient registry data and variable 
clinical indicators among samples of combined pediatric and adult patients to develop prognostic 
survival models. Characteristics of prognostic survival models, ease of use, and applicability to 
research and clinical practice among adults with CF were identified. Of the models reviewed, 
one, the CF-ABLE, lends itself to ease and applicability to adult CF clinicians and researchers. 
Future research should include development of models inclusive of clinical determinants 
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reflective of the latest prognostic factors among adult CF outcomes research and be validated 
among different national registries and their contributing centers.  
Introduction 
 Cystic fibrosis of the pancreas was first characterized by Dr. D.H. Anderson in 1938.  
Since that time, over 1,700 mutations of the CF transmembrane conductance regulator, or CFTR 
gene, have been recorded (CFF, n.d.).  Researchers have identified and reported numerous 
clinical indicators that impact the disease severity and prognosis (CFF, 2016).  The flawed CFTR 
gene contributes to the complications of many organ processes among patients with CF, thus 
accounting for differences in clinical presentations and severities of the disease (Carpenter& 
Narsavage, 2004).  Health outcomes, as well as clinical indicators of prognosis vary greatly. 
After decades of research and clinical advancements, agreement among CF researchers regarding 
which health indicators and at what level of physical functioning both the clinician and patient 
should base their health management decisions has yet to be determined; nor has a simplistic 
prognostic measure been widely accepted. 
Clinical Determinants 
 Determinants of mortality among patients with CF have been established and clinical 
deterioration and progression to death among CF patients has also been attributed to lung 
infection and colonization by microbials (Courtney et al., 2007; Dasenbrook, Konstan, & 
VanDevanter, 2015; Kalish et al., 2006), frequency of pulmonary exacerbation (Dasenbrook et 
al., 2015; Kanga, Kuhn, Craigmyle, Haverstock, & Church, 1999), CF-related diabetes (Adler, 
Shine, Haworth, Leelarathna, & Bilton, 2011; Kerem, Reisman, Corey, Canny, & Levison, 
1992), gender (Kerem et al., 1992), phenotype (Hafen et al., 2008) and nutrition (Courtney et al., 
2007; Fogarty, Britton, Clayton, & Smyth, 2012.)  
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A recent 7-year follow up study among a cohort of adults living with CF identified 
pulmonary artery systolic pressure ≥42 mm Hg and Forced Expiratory Volume or FEV1of ≤30% 
were significant predictors of poor outcomes (Flores et al., 2016). There is general agreement 
that respiratory decline, specifically a reduction in FEV1, is the leading prognostic indicator of 
survival among CF patients (Kerem et al., 1992; Sanders, Bittner, Rosenfeld, Redding, & Goss, 
2011; Yankaskas & Mallory, 1998).  
Disease Severity Scores 
Scoring systems were first introduced to identify disease severity and assist clinicians and 
guide decisions about treatment protocols (Shwachman & Kulczycki, 1958). These scoring 
systems were subjective and progressed slowly, with only a slight modification introduced by 
Doershuk and colleagues (1964) due to the phenomenon of increased survival among those with 
CF. Clinicians and researchers were limited to the subjective scoring systems prior to the 
development of the simplified CF scoring system (SCS), which was the first objective clinical 
scoring system for CF patients (Cooperman, Park, & McKee, 1971). The SCS (1971) was 
weighted heavily on lung health, which aligns with today’s standard of noting pulmonary decline 
as a primary diagnostic and prognostic measure of health outcomes (Dodge, Lewis, Stanton, & 
Wilsher, 2007). However, with the SCS only including two activity scores (“engages in athletics 
with normal peers”’, and “misses not more than 2 school days per month”) (Cooperman et al., 
1971), this historical scoring system is outdated for both the current primary adult CF population 
and known indicators of disease progression. Modern disease severity scoring systems have been 
constructed to reflect that CF is an autosomal recessive genetic disorder (CFF, 2016). 
Researchers have adapted these tools to account for phenotype expressions (Hafen, et al., 2008).   
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Variability among CF patients’ clinical presentation and an aging adult CF population 
prompts inclusion of known predictors of survival in addition to lung function when conducting 
outcomes research. Additionally, statistically significant indicators of mortality should be 
combined for the construction of prognostic models as they may assist clinicians with 
individualized treatment, validation of current therapy and self-management, optimization of 
transplant timing, or determination for end of life discussions and planning (Dodge et al., 2007); 
Flores et al., 2016).   
The purpose of this paper is to evaluate the prognostic survival model systems for adults 
with CF. Specifically, we aim to describe the characteristics of the CF prognostic models and 
their indicators of survival, ease of use, and applicability to research and clinical practice.  
Methods 
 We completed an electronic search of PubMed, CINAHL, OVID, ProQuest and Google 
Scholar databases and included search terms “cystic fibrosis”, “prognostic”, “adult”, and 
“predicted survival”. The location of the CFTR gene was first disseminated to the research 
community in 1989, therefore, database searches included articles published 1990-2017.One 
hundred and twenty-four citations were located. A hand search of references provided 16 
additional articles. After removal of duplicates, a total of 127 abstracts were reviewed (Figure 2). 
Inclusion and Exclusion Criteria 
  Articles written in English in which more than one clinical determinant of disease 
severity and prognosis were combined in the construction of a predictive model or score were 
included along with researchers reporting on the generation of a new prognostic model. Hayllar 
et al. (1997), included patient data collected between 1969 through 1987. Studies where the 
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majority of data was collected before1990 were excluded. Validation only studies were also 
excluded from evaluation. Studies without adult population samples were also excluded. 
Results 
 Following appraisal of inclusion and exclusion criteria, full print copies and any available 
supplemental materials of the final six articles were obtained for evaluation. We identified the 
following information:  first author, country, journal, publication year, study sample, validation 
sample, clinical indicators selected, predictive value, and prognostic outcome.  
Characteristics of the Literature 
 A summary of the research evaluated is displayed in Table 1. The publications extend 
sixteen years from 2001 to 2017, representing CF patient data collected as early as 1986. Since 
the discovery of the CFTR gene, researchers have developed models from CF populations in 
several countries including one each from Canada (Aaron, Stephenson, Cameron, & Whitmore, 
2015), France (Nkam et al., 2017), Ireland (McCarthy, Dimitrov, Meurling, Gunaratnam, & 
McElvaney, 2013), and Italy (Buzzetti et al.,  2011), and two from the United States (Liou et al., 
2001; Mayer-Hamblett, Rosenfeld, Emerson, Goss, & Aitken, 2002.)  
Sample sizes ranged between 49 patients from a single center to over 14,000 patients 
from registry data collected from more than 100 CF centers spanning an entire country.  
Researchers included both pediatric and adults during development of four prognostic models 
reviewed (Aaron et al., 2015; Buzzetti et al., 2011; Liou et al., 2001; Mayor-Hamblett et al., 
2002), with their subjects ranging in age from three to 62 years of age. Researchers included 
adult-only samples in two models reviewed (McCarthy et al., 2013; Nkam et al., 2017) with 
subjects ranging 20 to 32 years of age. Model validation procedures implemented by the 
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researchers during testing of each of the prognostic models is outlined in Table 2. Only one of 
the prognostic models reviewed utilized external validation methods (McCarthy et al., 2013).   
We reviewed the models’ study samples, development, validation, the researchers’ choice 
and variability of clinical indicators selected, and the ease by which clinicians may translate use 
of the prognostic survival model to research or practice. Models with predictive values of 1 year 
(Aaron, et al., 2015), 2 years (Mayer-Hamblett et al., 2002), 3 years (Nkam et al., 2017), 4 years  
(McCarthy et al., 2013), and 5 years (Buzzetti et al., 2011; Liou et al., 2001) , with prognostic 
outcomes of survival (Aaron et al., 2015; Buzzetti et al., 2011; Liou et al., 2001; Mayer-
Hamblett et al., 2002; McCarthy et al., 2013; Nkam et al., 2017), exacerbation (Aaron et al., 
2015), and transplant referral Mayer-Hamblett et al., 2002; McCarthy et al., 2013; Nkam et al., 
2017) were developed and evaluated.  
Lung function alone guided models predicting risk previously, however, researchers 
incorporated several commonly measured clinical indicators in the studies we reviewed. 
Statistically significant clinical indicators included, age (Aaron et al., 2015; Liou et al., 2001; 
Mayer-Hamblett et al., 2002; McCarthy et al., 2013), age at diagnosis (Aaron et al., 2015), 
gender (Aaron et al., 2015; Liou et al., 2001), delta F508 mutation (Aaron et al., 2015), height 
(Mayer-Hamblett et al., 2002), body mass index or BMI (Aaron et al., 2015; McCarthy et al., 
2013; Nkam et al., 2017),  and weight (Aaron et al., 2015; Liou et al., 2001).  
Clinical indicators associated with pulmonary status included exacerbation (Aaron et al., 
2015; Buzzetti et al., 2011; Liou et al., 2001; Nkam et al., 2017; Mayer-Hamblett et al., 2002), 
FEV1 % predicted (Aaron et al., 2015; Buzzetti et al., 2011; Liou et al., 2001; Mayer-Hamblett et 
al., 2002; McCarthy et al., 2013; Nkam et al., 2017), long-term oxygen therapy (Nkam et al., 
2017), lung function (Aaron et al., 2015), and non-invasive ventilation (Nkam et al., 2017).  
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Clinical indicators identified by organism included  P. aeruginosa colonization (Aaron et al., 
2015; Mayer-Hamblett et al., 2002), and S. aureus colonization (Buzzetti et al., 2011; Liou et al., 
2001), and B. cepacia colonization (Buzzetti et al., 2011; Liou et al., 2001; Mayer-Hamblett et 
al., 2002; Nkam et al., 2017).  
Clinical indicators associated with medication comprised of IV antibiotics (Mayer-
Hamblett et al., 2002; McCarthy et al., 2013; Nkam et al., 2017) and oral corticosteroids (Nkam 
et al., 2017). Other clinical indicators included diabetes (Aaron et al., 2015; Liou et al., 2001), 
and pancreatic insufficiency/sufficiency (Aaron et al., 2015; Liou et al., 2001).  
Ease of Use  
 The six prognostic models reviewed included two that could be calculated independent of 
statistical analysis software (Liou et al., 2001; McCarthy et al., 2013). Liou and colleagues 
(2001), provide worksheets on the publication’s journal website to assist clinicians with 
calculating the five year survival prediction for one patient. The worksheets encompass twenty 
steps of entering the nine patient clinical indicators or outcomes for tabulation into a ‘raw score’ 
that corresponds with a percent prediction of survival in increments of five from 5-95% (Liou et 
al., 2001).   
McCarthy and colleagues (2013) constructed an ‘ABLE score’ (age, BMI, lung function, 
and exacerbations) which clinicians and researchers can hand-tabulate by inputting the sums 
from each of the four clinical indicators and adding the assigned scores from the model (Table 
3). Patients who score >5 have a greater risk of poor outcomes within four years and may be 





Applicability to Research and Practice 
All of the models reviewed were objective measures and as such, are more robust against 
researcher, clinician, or patient bias. Of the six prognostic models reviewed, the CF-ABLE is one 
of two that can be scored independently of statistical software. This in addition to its utilization 
of everyday clinical parameters and the collection of both local electronic medical record and 
national patient registry data exclusively among adults with CF to develop and validate the CF-
ABLE, make it a beneficial prognostic tool for use in both adult CF research and clinical 
practice. The ease of utilization within the complex workflow of the clinical setting is an 
important asset for practitioners, as it may increase the likelihood of accurate and thorough 
administration and completion of a prognostic model.  
The CF-ABLE is more clinician friendly as it examines four clinical indicators in 
comparison to the 5-year survivorship model by Liou and colleagues (2001) that includes nine 
clinical indicators and outlines a process including upwards of 20-steps, which may need to be 
hand tabulated if readily available statistical software is not an option. The CF-ABLE includes 
clinical indicators that are attainable at clinic visits during a history and physical assessment and 
an easily and frequently administered lung function test result. The CF-ABLE scores are simple 
and cost effective and include tabulation instructions published with their supplemental 
materials.  
The CF-ABLE model lends itself to clinicians and researchers interested in CF outcomes 
as its clinical indicators account for lung health, nutrition, and age, all of which are common 
indicators of CF health outcomes (CFF, 2016). McCarthy and colleagues (2013) developed the 
CF-ABLE model utilizing an adult only sample and with adults accounting for over half of the 
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CF population today, the CF-ABLE’s development was more aligned with today’s researcher 
and clinician.  
The CF-ABLE is simplistic in clinical indicator selection, score tabulation, and 
prognostic evaluation for ease of translation; therefore, adult patients are better able to 
understand the applicability and meaning of this prognostic scoring method. Ease of use can 
assist the clinician with involving adult CF patients in care participation and facilitate disease 
specific education as well as motivational interviewing for patient-directed goal setting.  
Discussion 
We described the characteristics of prognostic survival model systems and provided an 
overview of model development, validation, predictive values, and prognostic outcomes. We 
also evaluated the models for applicability to research and clinical practice among adults with 
CF.  
The 5-year survivorship model (Liou et al., 2001) and the CF-ABLE score (McCarthy et 
al., 2013) were found to be adaptable to the clinician’s or researcher’s ability to easily obtain 
data from clinical settings and their prognostic values could be tabulated without the need for 
statistical software. Both of these models were variable in clinical indicator selection, although 
only the CF-ABLE was exclusive to the adult population during development and validation.  
Five of six studies utilized a CF patient registry in their development or validation of the 
models (Aaron et al., 2015; Liou et al., 2001; Mayer-Hamblett et al., 2002; McCarthy et al., 
2013; & Nkam et al., 2017), thus increasing the available sample sizes and adding to the 
statistical significance and accuracy of the prognostic survival models. During development of 
the “parsimonious model”, Buzzetti and colleagues (2012) limited their clinical indicators to 
only those having an interaction with lung function. The other five prognostic models reviewed 
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included varying combinations of clinical indictors. Therefore, generalizability of the prognostic 
models reviewed for clinicians and researchers interested in outcomes research among adults 
with CF may be challenging without first clearly understanding the relationship between the 
intended goals of their endeavor and limitations of their measurement capabilities.  
All of the models evaluated included clinical indicators that can be objectively measured. 
Including self-reported measures may assist researchers and clinicians with capturing patient 
perception information, thereby potentially improving the sensitivity of models for predicating 
exacerbation frequency, while providing insight into transplant referral and survival. 
Researchers, who have studied aspects of patient-reported health-related quality of life, 
determined items on a subjective questionnaire in the domains of physical functioning, “My CF 
has prevented me from getting out of the house to run errands”, pain, “How much did pain 
interfere with your normal work (including work both outside the home and at home)”, and 
social functioning, “I find that the way in which CF affects my socializing interferes with my 
overall enjoyment of life”, along with changes in health predicted survival, “Compared to one-
year ago, how would you rate your health in general now”, served as prognostic indicators of 
survival among CF sufferers in the U.K. (Abbott et al., 2009). Similarly and more recently, the 
physical functioning and health perception scales of the patient-reported CF Questionnaire 
(CFQ-R) showed promising results as reliable indicators of mortality (Sole et al., 2016).  
Limitations 
 This review is not without limitations. First, the review was limited to studies published 
in English and therefore may have excluded relevant articles from evaluation.  All but one study 
utilized patient registry data which may introduce information and/or selection bias, as not all CF 




This review suggests a reliable prognostic survival model which is easily adaptable to 
research and practice exists. The majority of those living with CF worldwide are adults, therefore 
priority should be given to development of prognostic models that are easily applicable to adult 
care environments. Clinical determinants of the models should reflect the latest prognostic 
factors among adult CF outcomes research and be validated among different national registries 
and contributing centers, allowing the researchers to work collectively toward increasing the 
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Table 3  
Calculation of the CF-ABLE Score (McCarthy et al., 2013) 
CF-ABLE Score Points 
Average FEV1 for last 3 months is ≥ 52.8 0 
Average FEV1 for last 3 months is < 52.8 3.5 
No. of Exacerbations needing IV Antibiotics in last 3 months ≤ 1 0 
No. of Exacerbations needing IV Antibiotics in last 3 months > 1 1.5 
BMI ≥ 20.1 0 
BMI < 20.1 1 
Age ≥ 24 0 
Age < 24 1 
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CHAPTER III:  SELF-MANAGEMENT BEHAVIORS AND HEALTH OUTCOMES AMONG 
ADULTS LIVING WITH CYSTIC FIBROSIS 
 Chapter III is a manuscript describing the findings of a longitudinal, descriptive repeated 
measures study exploring improved health outcomes among adults living with cystic fibrosis 
who reported adherent self-management behaviors regarding their prescribed treatment plan. The 
manuscript is planned for submission to Journal of Cystic Fibrosis, or Chronic Illness.  
Abstract 
Modern advances in research and treatment have resulted in an increased number of 
adults living with cystic fibrosis (CF), but with shortened life expectancy and high treatment 
burden. An aging CF population requires daily adherence to an arduous prescribed treatment 
plan. Despite critical importance for health outcomes, there is a lack of research focusing on self-
management by adults with CF using a prescribed treatment plan. A longitudinal, descriptive 
repeated measures design was conducted among adults with CF. We used self-report and a novel 
adult health outcomes measure during three clinic visits (enrollment, 3 and 6 months following 
enrollment) to ascertain the feasibility of determining if adults who were adherent to a prescribed 
treatment plan over time had improved health outcomes. Subjects adhered to their maintenance 
antibiotics, nutrition/digestion, and disease modifying treatments.  No significant visit effects or 
interaction between visits and adherence were identified. However, adherence to all disease 
modifying treatment did produce a statistically significant difference on health outcomes (p = 
0.014), with those who adhere to all disease modifying treatment (M = 0.67, SD = 1.22) scoring 
lower on health outcomes than those who do not adhere (M = 2.50, SD = 1.93). Health outcomes 
improved for those participants in our study who adhered to their disease modifying treatments, 
showing a statistically significant reduction in risk for transplant or death within the next four 
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years. Additional inquiry into adherence levels and barriers to maintaining adherence among 
adults with CF is warranted. 
Introduction 
Physicians diagnose 1,000 new cases of CF each year (Cystic Fibrosis Foundation [CFF], 
2016a). This incurable, progressive, multisystem disease harms numerous organs, primarily the 
pulmonary and digestive systems, complicates many of the body’s normal processes, and 
shortens life expectancy. Until recently, people living with a diagnosis of CF rarely reached 
adulthood. Today, over half of the CF patient population are eighteen years of age or older and it 
is predicted that a person diagnosed with CF has a life expectancy of 40 or more years (CFF, 
2016a).  
 The prescribed treatment plan for CF is highly complex and time consuming requiring 
two to four hours each day to complete a prescriptive treatment plan (Figure 3). Typically, adults 
with CF must perform airway clearance, inhale antibiotics or aerosols to dilate airways, thin or 
clear mucus, utilize inhalers, consume pancreatic enzymes with every meal or snack, incorporate 
nutritional supplements and vitamins into their diet, ingest oral antibiotics, perform chest 
physiotherapy, engage in aerobic exercise, and maintain a daily caloric intake sufficient to 
maintain weight (CFF, 2017; Quick & Byrd-Bredbenner, 2015). In addition, some may be 
prescribed disease modifying medication if their gene phenotype testing aligns appropriately 
(CFF, n.d.) 
Recommendations are not followed in about 50 percent of those living with CF and is most 
likely due to challenges with finding up to four hours daily to complete the entire regimen (Elborn, 
2016; Latchford, Duff, Quinn, Conway, & Conner, 2009). If they do not implement these 
recommended tasks several times per day and rid the lungs of excess mucus, people with CF will 
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increase their likelihood of bacterial growth and colonization, leading to possible pulmonary 
exacerbation and reduced lung function, health decline, and possibly death (CFF, n.d.).  
Medication adherence, or the extent by which a patient takes medications as prescribed 
(Khanna, Pace, Mahabaleshwarkar, Basak, Datar, & Banahan, 2012) varies in CF and is 
estimated to range from approximately 35-75% depending on the measure, medication, and 
population characteristics (Eakin & Reikert, 2013; Tappenden, Sadler, & Wildman, 2017). 
According to the CFF (2012), nearly one in every five CF patients has reported skipping doses of 
medication or delaying treatment due to costs. The average annual economic burden for one 
person’s CF treatment is more than $40,000 and due to the rising costs related to recommended 
treatments and therapies, insurance premiums have increased 20% for people living with CF 
(CFF, 2012). Maintaining the prescribed level of care can cost an adult living with CF over 
$300,000 in their lifetime (Rubin, Thayer, Watkins, Wagener, Hodgkins, Schechter, 2017). This 
high economic and treatment burden prompts the CF healthcare community to work to provide 
evidence-based treatment and adherence recommendations.  
With life-threatening complications associated with the need for adherence, healthcare 
professionals require insight into which adherence categories are most impactful among adults 
living with CF. Currently, adherence to treatments in categories such as airway, digestion, 
disease-modifying, and infection-control are necessary to maintain health (Briesacher, Quittner, 
Saiman, Sacco, Fouayzi, & Quittell, 2011). Importantly, there is a need for studies investigating 
a relationship between adherence to prescribed self-management regimes and health outcomes 
(Tappenden et al, 2017). Limited evidence regarding adherence to treatments as they relate to 
health outcomes  constrains the ability of health professionals to make population sensitive 
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recommendations. There is minimal research on adherence and health outcomes among adults 
with CF.  
Problem 
Adults living with CF now outnumber children in this population and as more reach 
adulthood, live independently and encounter adult life challenges, recommendation for self-
management require change (CFF, 2017). For decades, researchers have focused on children and 
adolescents with CF, but this childhood disease has progressed into one predominantly of 
adulthood, with little research focus on adults. An aging CF population requires continuous self-
management and adherence to multiple treatments and medications (CFF, 2017). Studies aimed 
at understanding the impact of adherence to the components of the treatment plan on outcomes 
of adults self-managing is paramount. Preventing additional societal and economic costs 
associated with avoidable hospital admissions, morbidity, and mortality among adults living with 
CF is possible, with the appropriate research and recommendations addressing this population. 
However, the CF self-management literature lacks an exclusive focus on the adult and the impact 
of adherence to their prescribed treatment plan on health outcomes..  
A documented understanding regarding self-management of the overall prescribed 
treatment plan and impact to health outcomes among adults living with CF does not exist. 
Researchers have explored the experience of living with and managing CF for children (Dashiff, 
Suzuki-Crumly, Kracke, Britton, Moreland, 2013; Goodfellow, Hawwa, Reid, Horne, Sheilds, 
McElnay, 2015; Jamieson, Fitzgerald, Singh-Grewal, Hanson, Craig, & Tong, 2014); adolescents 
and young adults transitioning from having assistance with their prescribed treatment plan to self-
management (Al-Yateem, 2012; Tierney, Deaton, Jones, Oxley, Biesty, & Kirk, 2013); the 
experience of CF patient siblings (Havermans et al., 2011); as well as parents and caregivers of 
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CF patients (Barker & Quittner, 2016; Goodfellow et al., 2015; Sawicki, Heller, Demars, & 
Robinson, 2015).  
Efforts to quantify necessary adherence within the self-management regime may facilitate 
development of more manageable, patient-centered prescribed treatment plans, improve upon 
self-management behaviors, and influence health outcomes among adults with CF.  We explored 
the feasibility of identifying categorical adherence and health outcomes among adults with CF 
when utilizing self-report and a novel health outcome measure. The purpose of this study was to 
examine the relationship between specific adherence behavior and health outcomes over time; 
this may enable health professionals to promote adherence considering the unique nature of the 
self-management experience among adults living with CF.  
Research Questions 
We hypothesized adherence over time to a prescribed treatment plan would result in 
better health related outcomes among adults living with CF. The following research questions 
were addressed: 
1. What was the change in health outcomes over visits: (enrollment, 3 months following 
enrollment, 6 months following enrollment)? 
2. What is the difference in health outcomes based on adherence to prescribed treatment 
categories:  
 all disease modifying (targeted CF protein treatments acting at cellular level);  
 all nutrition/digestion-aid (pancreatic enzymes, diet, supplements, vitamins);  
 all maintenance antibiotics (oral and inhaled antibiotics)? 
3. Did health outcomes differ by the interaction between visits and adherence to 




 Effective treatments have been developed and contributed to the extensions of life for 
tens of thousands of people diagnosed with CF, however, patients are not fully participating in 
their prescribed care. The following is a brief overview of self-management and adherence to 
provide insight into the challenges faced within the CF population.    
Self-Management  
In the context of chronic illness, self-management refers to the attitudes and activities 
individuals adopt to maintain wellness, control symptoms, and prevent acute and chronic 
complications (Richard & Shea, 2011). Self-management has been linked to improved health 
status, increased quality of life, continued independence, and decreased medical costs (Flanagan, 
Damery, & Combes, 2017; Kash, Lin, Baek, & Ohsfeldt, 2017).  
For a person with CF, aggressive and arduous CF treatments are required daily, and self-
management behaviors may include performing chest physiotherapy, use of airway clearance 
devices, taking prescribed medications, monitoring respiratory and nutritional status, 
implementing infection control measures, care for anxiety and depression, and boosting calories 
to 110% to 220% of the recommended daily allowance (CFF, n.d.; Quick & Byrd-Bredbenner, 
2015; Quittner et al., 2012). New approaches to medication and therapeutic treatment, such as 
innovative drug trials for gene and molecular therapies, are emerging and adding to an already 
burdensome health maintenance regime (Elborn, 2016).  These innovative treatments will require 
time consuming lab testing processes and arduous navigation of forms required for insurance 
approvals and payment coverages, as well as additions to the care team, such as a research team; 
this may lead to increased visit time or number of visits in an already complex multidisciplinary 




Adherence is a necessary component in self-management of CF. The impact of adherence 
among those with CF has been attributed to significant variation in patient outcomes (Hebestreit 
et al., 2018; Knudsen et al., 2016; Zemanick et al., 2010). Researchers indicate poor self-
management skill is associated with pulmonary exacerbation and lower baseline lung function 
(Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011; Eakin & Reikert, 2013; Tappenden et al., 
2017). Studies in adherence among adults with CF suggest similar rates as other chronic 
diagnoses (Lin, Kendrick, Wilcox, & Quon, 2017; Sawicki, Sellers, & Robinson, 2009). 
However, adults living with CF require adherence to a varied and complex daily regime, frequent 
follow up visits with multiple health specialists, and constant self-monitoring, which makes 
multiple-adherent behaviors necessary for better health outcomes.  
 Researchers report lower baseline lung function (Eakin et al., 2011), higher costs (Nasr, 
Chou, Villa, Chang, & Broder, 2013), and increased hospitalizations (Briesacher et al, 2011) are 
associated with poor adherence to CF medications. In one study, investigators (Eakin et al, 2011) 
enrolled CF patients six years of age and older and reported poor adherence to nebulized 
medication was a significant predictor of having a pulmonary exacerbation requiring intravenous 
(IV) antibiotic therapy. Historically, adherence researchers limited their studies to one 
medication or therapy and included children and adolescents, in addition to adults in samples.  
The majority of CF patients are facing life challenges that are different than those of the 
child and adolescent and without an emphasis on the adult living with CF, researchers will be 
unable to account for their needs. Researchers must capture the lived experience of aging with 
CF in study design and prepare for subjects that are primarily self-managing their disease. 
Today’s researchers should postulate psychosocial and time factors playing a role in adherence 
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among adults with CF (Lin et al., 2017).  Despite the decades of exposure to the same prescribed 
treatment plan typical of childhood diagnosis, the adherence levels among adults with CF are 
low and similar to others with chronic illness (Quittner et al, 2014; Reikert, 2009).  
Theoretical Framework 
The multifactorial causes of variability in outcomes model (Zemanick et al., 2010) guided 
this feasibility study (Figure 4). The current model was modified from Schechter’s (2003) 
original introduction and connects the known constructs that may be acting on outcomes among 
adults living with CF. The causes of variability model (Zemanick et al., 2010) is specific to CF 
and identifies factors that are consistent with known research regarding management, modifiable 
and non-modifiable variables, as well as, known outcomes among adult CF patients. The model 
includes multiple variables within the spheres of genetic factors, medical treatments, and 
environmental exposures. Each sphere of the model was useful in the selection of measures and 
informing on variables pertinent to adherence and outcomes research among adults with CF. 
Within the sphere of medical treatments, Zemanick and colleagues (2010) identified that 
adherence may be influencing outcomes. Too little available research makes it difficult to 
establish the exact amount of adherence needed to attain health benefits in this population 
(Reikert, 2009). Longitudinal studies are needed to better measure the degree to which varying 
adherence patterns affect health outcomes and whether the strength of associations differ by 
subgroups among those living with CF (Jennings, Riekert, & Boyle, 2014). The adult CF 
community lacks adult-sensitive research exploring the existence of relationships between the 
spheres outlined by Zemanick and colleagues (2010) and also quantifying overall adherence 
influencing health outcomes.  
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 Zemanick and colleagues (2010) stressed that understanding the influence of self-
management behaviors upon outcomes is a critically important task to advancing CF care. 
Therefore, we believe the multifactorial causes of variability in outcomes model (2010) to be a 
useful framework to guide research regarding self-management behavior, such as adherence, 
among adults living with CF.  
Methods 
Design, Setting, and Sample  
This feasibility study used a descriptive, longitudinal repeated-measures design. We 
obtained approval from both the University and the healthcare institutional review boards.  A 
convenience sample of 18 participants was recruited from a clinic providing healthcare services 
to a minimum of 50 adults with CF. Inclusion criteria were participants: with a diagnosis of CF 
made at least one year prior to study entry, ≥18 years of age, and were current patients of a 
Midwestern adult CF clinic accredited by the National CF Foundation (CFF). Exclusion criteria 
were participants who had a documented cognitive or physical impairment prohibiting them from 
completing the research instruments independently or those who were unable to understand the 
written and/or spoken English language.  
Measures 
Demographic and other data. We collected health measurements and demographic data 
from the electronic medical record or EMR as well as prescribed medications and treatments. 
This information was utilized to describe our subjects, calculate health outcome scores, and 
determine adherence. Table 4 outlines a list of theoretical and operational definitions of the 
information collected.   
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CF-ABLE score. A change in health outcomes in this study was identified by CF-ABLE 
scores (McCarthy, Dimitrov, Meurling, Gunaratnam, & McElvaney, 2013). Health outcomes 
scores were calculated from the sum of the individual component scores and were determined by 
the following: ABLE score [0.0-7.0] = FEV1 % predicted (mean previous 3 months) [0.0-3.5] + 
number exacerbations (previous 3 months) [0.0-1.5] + age at time of assessment x BMI [0.0-2.0] 
as identified by McCarthy and colleagues (2013, p.1362).  
The CF-ABLE score (McCarthy, 2013) utilizes clinical parameters designated ‘ABLE’, 
[age (A), body mass index or BMI (B), lung function (L) expressed as forced expiratory volume 
in one second (FEV1), and number of pulmonary exacerbations (E) in the previous 3 months], to 
predict health outcomes among patients with CF (Table 5). Specifically, the score is a prognostic 
indicator, which assists clinicians with predicting risk of death or lung transplant within four 
years, as validated during a five-year period utilizing 370 patients from the national CF Registry 
of Ireland (CFRI).  When the researchers applied the CF-ABLE score to the registry data, there 
was a significant (p < .001) difference found between subgroups of good outcomes (M = 2.61, 
SD = 2.15) and poor outcomes (M = 5.21, SD = 1.30); discriminative performance was 
confirmed by ROC curve analysis (95% CI, 0.77 - 0.88). The researchers validated that the 
logistic regression model was accurate at predicting death or transplant within the studied cohort.   
On average, McCarthy et al. (2013) found a 1-point increase of the CF-ABLE score 
would lead to an 81% increase in risk of poor outcome within four years (OR, 1.81; 95% CI, 
1.46-2.22). The variables included were identified as the best model after a number of them 
(including gender and genotype) were correlated as potential predictors of death or lung 
transplant. Each variable’s cut-off levels were identified utilizing statistical analysis and/or 
clinical judgment and then were used to create parameters for “high-risk” (score 5 – 7) and “low-
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risk” (score < 2). The resulting score is simple, applicable, and better predicts outcome than 
FEV1 alone (McCarthy et al., 2013).  The researchers further incorporated the clinical application 
of the score over two years following development and reported the tool to be useful and 
concisely predictive of patient prognosis among their subjects (Meurling, McCarthy, 
Gunaratnam, & McElvaney, 2014). To date, no other studies have been located which utilized 
the CF-ABLE. 
Treatment adherence questionnaire for cystic fibrosis. Inclusion of self-report 
measures of adherence are cost effective and comprehensive with all aspects of the management 
regimen, many of which cannot be measured objectively; they also can assess adherence over 
longer periods of time (Quittner et al, 2014). The use of self-report measures for the study of 
adherence rates consistently demonstrate high specificity in that patient reports of non-adherent 
behaviors are valid (George et al., 2010; Quittner et al., 2014).  
 Figures 5 and 6 identify the Treatment Adherence Questionnaire for CF, or TAQ-CF 
(Quittner, Espelage, Ievers-Landis, & Drotar, 2000; Quittner et al., 2012), which has replaced 
both the Disease Management Interview-CF, or DMI-CF (Quittner et al., 2000), and the 
Treatment Adherence Rating Scale, or TARS (DeLambo, Ievers-Landis, Drotar, & Quittner, 
2004). The TAQ-CF does not require specialized training to administer and comprehensively 
addresses components of the treatment regimen for CF, which is particularly important as 
treatment may vary across CF centers and physicians (Quittner et al., 2000; Quittner et al., 2012). 
The TAQ-CF is a brief, self-report questionnaire concentrated on twelve of the prescribed 
treatments specific for CF and asks subjects to recall and document their frequency, duration, 
and barriers for each treatment during the previous week. 
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 Efforts to improve the quality of documented adherence behavior includes application of 
nonjudgmental language in the instructions for the respondents utilizing the TAQ-CF, which 
normalized the possibility of missed treatments by stating, “You’re not alone if you’ve missed 
medications or treatments. It is hard to fit it all in everyday” (Quittner, Modi, Lamanek, Ievers-
Landis, & Rapoff, 2008). Nonjudgmental language facilitates more honest and accurate 
responses (Rapoff, 2003). Prior studies demonstrated agreement between parents and teens on 
the TAQ-CF was moderate to high (r =.55 for aerosol medications, r =.78 for CPT), and test-
retest reliabilities over one year ranged from .62 to .73 for adolescent reports and .76 to .88 for 
parent reports (DiGirolamo, Quittner, Ackerman, & Stevens, 1997; Quittner et al., 1996). To 
date, no studies have been located utilizing the TAQ-CF with an adult sample, so a slight 
modification replacing ‘teens’ with ‘adults’ in the questionnaire directions’ statement was 
necessary.  
 From subjects’ report on the TAQ-CF, we identified adherence behavior, specific to the 
prescribed treatment plan and determined overall adherence by treatment including all disease 
modifying (targeted CF protein treatments acting at cellular level), all nutrition/digestion-aid 
(pancreatic enzymes, diet, supplements, vitamins), all maintenance antibiotics (oral and inhaled 
antibiotics), all airway-related treatment (inhaled, clearance device), and overall prescribed 
treatment. Of the five treatment adherence categories, none of the subjects adhered to overall 
prescribed treatment and all airway-related treatment, resulting in no further analysis. 
Procedure 
After consenting subjects, they each filled out a set of paper questionnaires. Each 
participant had their own new writing utensil at each data collection point to avoid cross-
contamination. Data was collected at enrollment, and then three months and six months post 
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enrollment. This data collection aligned with recommended CF clinic visit scheduling (CFF, 
2016a) and is the typical amount of time an average adult living with CF, should be self-
managing prior to clinical contact with their health provider. This time frame also allowed for 
calculation of a health outcomes score using our measure, which required three months of 
clinical data. We could then explore for the interaction between adherence to treatment over time 
and health outcomes within our sample. 
Data Analysis 
All calculations and summary statistics to describe the sample characteristics were done 
in IBM Statistical Package of the Social Sciences (SPSS) 22.0 (IBM Corp, Armonk, NY, 2013). 
The small sample size of 16 adults with CF led to insufficient power and the violation of 
required normality assumption for the initially proposed within-between repeated-measures 
ANOVA. As an alternative, an ANOVA-type statistics using “nparLD” package (Noguchi, Gel, 
Brunner, & Konietschke, 2012) in R was run to test the proposed hypotheses using the Brunner-
Langer nonparametric analysis of longitudinal data in factorial experiments. The main and 
interaction effects between overall adherence by treatment category and time on health outcome 
scores were examined. Bonferroni’s adjustment for Type I error was applied due to multiple 
testing so all statistical significances were reported at p ≤ 0.015. 
Results 
 We recruited 18 subjects, 16 completed data collection, with a response rate of 88.9%. 
One subject did not return for treatment and one died. Our sample characteristics illustrate 
similarities to adults living with CF today according to a recent CFF Patient Registry Annual 
Data Report representing nearly 84% of all CF patients in the United States (CFF, 2016b, 2017).  
Our sample included 62.5% (n = 10) of females, half (50.0%; n = 8) attended or completed 
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college, 62.5% (n =10) working full/part-time, and 68.8% (n=11) married/living together (Table 
6). All subjects had some form of insurance coverage through either an employer or government. 
Our sample’s genotypes included a majority with the most common mutation, homozygous delta 
F508 (56.3%); this mutation impacts almost 70% of all affected with CF worldwide (Stanford 
Medicine, 2017). Participants’ mean rating on a self-appraised stress questionnaire was high.  
Adherence Differences on Health Outcomes 
 To test differences between adherence groups for CF-able scores over visits, 
nonparametric within-between repeated measures ANOVAs were run. Further analyses were run 
on adherence to all disease modifying treatment, adherence to all nutrition/digestion-aid 
treatment, and adherence to all maintenance antibiotic treatment. Results of the CF-able scores 
are presented in Table 7 and Table 8.  
Health Outcomes Scores by Adherence to All Disease Modifying Treatment  
The effect of visits nor the interaction effect between adherence to all disease modifying 
treatment and visits did not reach statistical significance. However, patients’ adherence to all 
disease modifying treatment did produce a statistically significant difference on CF-able scores 
(p = 0.014), with those who adhere to all disease modifying treatment (M = 0.67, SD = 1.22) 
scoring lower than those who do not adhere (M = 2.50, SD = 1.93). 
Health Outcomes Scores by Adherence to All Nutrition/Digestion-aid Treatment 
 Neither visits nor the interaction between adherence to all nutrition/digestion-aid 
treatment and visits reached statistical significance. Patients adhering to all nutrition/digestion-
aid treatment (M = 1.75, SD = 1.91) were not found to be significantly different in CF-able 




Health Outcomes Scores by Adherence to All Maintenance Antibiotic Treatment 
 Like the case in the above two tests, neither visits nor the interaction between adherence 
to all maintenance antibiotic treatment and visits did not reach the statistical significance. 
Patients adhering to all maintenance antibiotic treatment (M = 2.29, SD = 1.95) were not found 
to be significantly different in CF-able scores from those adhering to all maintenance antibiotic 
treatment (M = 0.33, SD = 0.50). 
Discussion 
 This study explored a relationship between specific adherence behavior and health 
outcomes over time. We hypothesized adherence over time to a prescribed treatment plan would 
result in improved health related outcomes among adults living with CF. We also explored the 
feasibility of identifying categorical adherence [all disease modifying (targeted CF protein 
treatments acting at cellular level); all nutrition/digestion-aid (pancreatic enzymes, diet, 
supplements, vitamins); all maintenance antibiotics (oral and inhaled antibiotics)] and health 
outcomes among adults with CF when utilizing self-report and a health outcome measure. 
Our sample included subjects with a documented modifier gene (37.6 %); researchers are 
reporting that variability in disease severity and outcomes are likely influenced by modifier 
genes (Inacio, 2017; Vanscoy et al., 2007). It is noteworthy to mention efforts to study and 
document modifier genes among CF patients is underway to better understand the 
pathophysiology and progression of outcomes (Inacio, 2017). Disease modifying treatments are 
promising, as revealed in the study results. Health outcomes improved for those participants in 
our study who adhered to their disease modifying treatments, showing a statistically significant 
reduction in risk for transplant or death within the next four years. Additional inquiry into 
adherence levels and barriers to maintaining adherence among adults with CF is warranted, 
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which may enable health professionals to promote adherence while taking into account the self-
management experience for adults. 
Efforts to recognize the complexity of managing absolute adherence to the prescribed 
treatment regime overall while meeting the expectations of adulthood, such as independence, 
employment, financial responsibility, social-wellbeing, navigation of the healthcare system, and 
having a family of their own, should be considered among this population. Although  insurance 
coverage assures some form of assistance was available for all of our subjects, the existence of 
barriers to access and limited availability of care, medications, reimbursement, and durable 
medical equipment outlined by their carriers is well documented (Kraft, 2012; Lyon, Douglas, & 
Cooke 2014). The Perceived Stress Scale (PSS) results indicated higher stress levels among our 
sample than those found in the national norm group sample taken from over 2,400 U. S. 
respondents (Cohen, Kamarck, & Mermelstein, 1983; Cohen & Williamson, 1988). Higher levels 
on the PSS suggest the respondent’s self-perception of how unpredictable, uncontrollable, and 
overloaded they have found their life over the previous month and have been associated with 
difficulty self-managing chronic disease (Cohen et al., 1983).  The introduction of individualized 
adherence expectations may assist with motivation and self-efficacy to adhere.  
In this study, participants’ adherence to all nutrition/digestion-aid and maintenance 
antibiotics treatment had a non-significant relationship with health outcomes. It has been 
established that proper nutrition influences lung function; in addition, BMI and lung 
exacerbation are associated with mortality risk among CF patients (CFF, 2017; Courtney et al., 
2007; de Boer, et al., 2011; Fogarty, Britton, Clayton, & Smyth, 2012; Sanders, Bittner, 
Rosenfeld, Redding, & Goss, 2011). Obtaining a larger sample size is needed for future research. 
Further research could help support identification of a therapeutic individualized rate of 
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adherence by treatment category and adherence pattern which may be more manageable for 
adults living with CF and lead to improved quantity and quality of life.   
Implications for Future Research 
 Repeating the study across different CF clinics to obtain a large sample and including 
patients who are not under the care of a CF specialist, but are managed primarily by a 
pulmonologist or general practitioner, may provide variability and capture patients not diagnosed 
early in life. Future researchers may benefit from attempting to enroll patients identified as self-
managing well and not self-managing well by the CF clinic staff. Continuing to collect data, 
even when subjects are admitted to inpatient settings during exacerbation, or enrolling based 
upon a baseline health outcomes or prognostics scores to ensure a more representative sample of 
the population may also decrease threats to external validity. Including objective measures of 
adherence data, such as pill count devices, or pharmacy refill data is may lead to more reliable 
data collection in future studies. Also, identifying subjects’ knowledge regarding their prescribed 
treatment plan and the importance of adherence in relation to their health outcomes may provide 
needed insight into barriers not captured on the tools utilized in the current study.  
There is a need for future adult CF research to target development and refinement of 
adherence tools. A gold standard for adherence measurement is nonexistent and difficulty in 
obtaining adherence measures is well documented (Jennings et al., 2014; van den Boogaard, 
Lyimo, Boeree, Kibiki, & Aarnoutse, 2011). Objective measures of adherence can be expensive 
and insensitive to fluctuations in the variable adherence patterns of those self-managing CF 
(Quittner et al., 2014) but can be desirable for limiting bias found with some self-report 
measures. Patient health literacy and self-efficacy and their impact on adherence are important 
factors to consider (Quittner et al., 2008).  Our study collected information regarding current 
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stress levels experienced by subjects and barriers to adherence, including access. Smith and 
colleagues (2010) reported emotional symptoms had a significant impact on adherence, 
therefore, incorporating impact from stress and situations that can increase stress, such as 
healthcare access, on adherence discussions with adults could assist with tailoring intervention 
strategies.  
Strengths  
Socio-demographic characteristic data were explored for significant differences among 
those who participated, in an attempt to increase generalizability to the adult CF population. 
Accurate, consistent data collection by one researcher contributed to the internal validity of the 
study. Well-established measures were selected with reported psychometric properties and 
validity data. The CF-ABLE and TAQ-CF questionnaire, both novel to use with adults living 
with CF in the United States were utilized, broadening the tools’ exposure to the adult CF 
healthcare community.  
 Limitations  
Several limitations of the study are worth mentioning. First, data were collected in a 
single clinical outpatient setting with a small sample of patients. There was potential for response 
bias due to the convenience sample. Patients who were not feeling well may have not been 
motivated to participate and further reduced generalizability. Also, the self-report measure relied 
on accurate recall of information by the subject over time and this could have contributed to 
problems with external validity. Individuals who missed clinic appointments or were hospitalized 
were unavailable to enroll in the study and could have contributed to greater variability of health 
outcomes. Concerns regarding internal validity include level of nonresponse and discontinuing 




Ideally, future adult CF adherence research benefits include both participants and the CF 
healthcare community. Subjects who complete detailed survey tools could become acutely aware 
of successful self-management behaviors and have the potential to engage in dialogue regarding 
these expectations with their interdisciplinary teams. These teams have the capability of assisting 
to deepen health literacy, identify barriers, and encourage adherence behaviors among their adult 
patients. In our study, adherence in one area of a treatment plan produced a statistically 
significant change in health outcomes using a prognostic health indicator among a small sample. 
This finding could be helpful to clinicians and patients by highlighting that there are indications 
to explore the health outcomes potential of adherence to specific areas of CF treatment plans 
over others, thus altering the daily burden of current treatment plans from 100% compliance in 
all treatment areas to more variable adherence patterns.   
Current adult CF treatment plans are burdensome and lack insight into the potential of 
specific adherence patterns.  Additional research with a focus on the adult CF population may be 
useful to researchers and clinicians to evaluate health outcomes in the clinic setting, construct 
individualized, patient-centric treatment recommendations that account for current evidence and 
patient genetic testing. Research results may further aid health care professionals to promote and 
facilitate specific adherence levels among the adult CF population. The potential exists to 
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Theoretical and Operational Definitions of Key Demographic Variables EMR Review  
 






Dysfunctional protein in CF 
patients 
CFTR genotype variation Categorical 
Modifier genes 
Genetic variants responsible for 
complications of CF 
Expression of modifier genes Categorical 
Gender Biological expression Self-report as Male or Female Categorical 
Microorganisms Invading organism in the lungs 
Presence in sputum culture 
(Pseudomonas, MRSA, or other) 
Categorical 
Tobacco Smoke Exposure to tobacco smoke 
Smoker, Non-smoker,  
Lives with a smoker 
Categorical 
Nutrition 
Body fat indication based upon 
weight & height 
Calculated utilizing BMI                
(Body Mass Index) 
Continuous 
Stress Current level of stress experienced  
Perceived Stress Scale (PSS) 
questionnaire 
Continuous 
Age # of years since birth Date of Birth Continuous 
Age at Diagnosis Date of confirmed CF diagnosis Age at time of diagnosis Continuous 
CF Diagnosis 
Confirmation 
Diagnostic laboratory testing 
Dysfunction of CFTR (gene 
analysis), sweat test 
Continuous 
Prescribed Care 
Prescribed management behaviors, 
medications & treatments 
Prescribed Treatment Plan (PTP) 
as recommended by the CFF 
Categorical 
Adherence 
Frequency patient engages in 







Volume in 1 second) 
Measure of lung function Spirometer measurement Continuous 
Exacerbations 
Symptomology requiring IV 
antibiotics 
# in previous 3 months Continuous 
Insurance Status 
Ability for timely use of personal 
health services  






Table 5  
Calculation of the CF-ABLE Score (McCarthy et al., 2013) 
CF-ABLE Score Points 
Average FEV1 for last 3 months is ≥ 52.8 0 
Average FEV1 for last 3 months is < 52.8 3.5 
No. of Exacerbations needing IV Antibiotics in last 3 months ≤ 1 0 
No. of Exacerbations needing IV Antibiotics in last 3 months > 1 1.5 
BMI ≥ 20.1 0 
BMI < 20.1 1 
Age ≥ 24 0 
Age < 24 1 
Total Score: 0 – 7 Points  





Table 6  
 
Characteristics of the Sample (n = 16) 
 
Characteristic n (%) M (SD) 
Age (at time of enrollment) 
 



















Gross Annual Earnings 
Less than $25,000 
$25,000 to $49,999 
$50,000 to $74,999 
$75,000 to $99,999 












Heterozygous delta F508 
Homozygous delta F508 
 
Modifier gene identified 
 



























































































Table 7  
Descriptive Statistics for CF-ABLE Health Outcomes Score at Each Data Collection  
 Adherence 
No Yes 
Visit 1           
M +/- SD 
Visit 2           
M +/- SD 
Visit 3           
M +/- SD 
Visit 1           
M +/- SD 
Visit 2           
M +/- SD 
Visit 3           














2.27 +/- 1.93 2.62 +/- 2.04 2.00 +/- 1.98 0.33 +/- 0.57 0.33 +/- 0.57 0.33 +/-0.57 




Table 8  
Effects of Adherence, Time, and Their Interaction on Health Outcomes 
Treatment Category Statistic Df P value 
Disease modifying treatments 
        Adherence (No vs. Yes) 
        Visit (Visit 1 – Visit 3) 















        Adherence (No vs. Yes) 
        Visit (Visit 1 – Visit 3) 















Maintenance antibiotic treatments 
        Adherence (No vs. Yes) 
        Visit (Visit 1 – Visit 3) 



















Figure 3. Typical daily adult CF health maintenance requirements and frequency. 
Prescribed Treatment Plan, by Quittner, A. L., 2000, Retrieved from 
http://www.psy.miami.edu/ksa_measures/pub.phtml. Copyright [2011] University of Miami. 




Figure 4. The multifactorial causes of variability in outcomes model (Zemanick et al., 2010) 
Zemanick and colleagues modified from Schechter’s (2003) original introduction. Connects the 
known constructs that may be acting on health outcomes among a person with CF, including 
multiple variables within the spheres of genetic factors, medical treatments, and environmental 







Figure 5. TAQ-CF by Quittner et al., 2008, Retrieved from http://www.psy.miami.edu/ksa_measures/pub.phtml. Copyright [2011] 








Figure 6. TAQ-CF, modified for adult use with removal of ‘teens’, by Quittner et al., 2008, Retrieved from 
http://www.psy.miami.edu/ksa_measures/pub.phtml. Copyright [2011] University of Miami. Reprinted with permission. 
    What is getting in the way?
In the last week, how often did 
you do each treatment?
 How many minutes did you 
spend doing each 
treatment?
Most people find it hard to do all of their treatments each day for good CF care. Please tell us which treatments you have done 
over the last week.  You're not alone if you've been missing some medications and treatments. It is hard to fit it all in everyday. 
Please answer these questions honestly. Please check the box that is closest to your answer.                                                                                                                                          
RESEARCH#                                                                                 
_  _  _  _ -  _  _
Treatment Adhereance 
Questionnaire-CF            






































































































































































































































AEROSOLS TO OPEN AIRWAYS         
(albuterol, Xopenex  ®)
AIRWAY CLEARANCE                          
(CPT, Vest ®, Acapella ®)
OTHER  
______________________
AEROSOLS TO CLEAR MUCUS                  
(hy pertonic saline)
ORAL ANTIBIOTICS                                
(azithromy cin)
INHALED ANTIBIOTICS                        
(Colistin)
DISEASE-MODIFYING                          
(Kalv deco™)
NUTRITION                                                    
(3 meals + 2-3 snacks)
SUPPLEMENTS                                    
(Scandishake®)
VITAMINS                                                 
(ADEK, multiv itamin)
AEROSOLS TO THIN MUCUS         
(Pulmozy me®)
INHALERS                                              
(albuterol, Pulmicort®, Flov ent®)
PANCREATIC ENZYMES                     
(Creon®, Ultrase®)
